FR2847263B1 - Polynucleotide specifique de la cellule pancreatique beta des ilots de langerhans - Google Patents

Polynucleotide specifique de la cellule pancreatique beta des ilots de langerhans

Info

Publication number
FR2847263B1
FR2847263B1 FR0214374A FR0214374A FR2847263B1 FR 2847263 B1 FR2847263 B1 FR 2847263B1 FR 0214374 A FR0214374 A FR 0214374A FR 0214374 A FR0214374 A FR 0214374A FR 2847263 B1 FR2847263 B1 FR 2847263B1
Authority
FR
France
Prior art keywords
cells
sequence
nucleic acid
protein
iia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0214374A
Other languages
English (en)
French (fr)
Other versions
FR2847263A1 (fr
Inventor
Michel Seve
Alain Favier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Joseph Fourier Grenoble 1
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Original Assignee
Commissariat a lEnergie Atomique CEA
Universite Joseph Fourier Grenoble 1
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0214374A priority Critical patent/FR2847263B1/fr
Application filed by Commissariat a lEnergie Atomique CEA, Universite Joseph Fourier Grenoble 1 filed Critical Commissariat a lEnergie Atomique CEA
Priority to US10/535,395 priority patent/US7851164B2/en
Priority to DE60323664T priority patent/DE60323664D1/de
Priority to CN2011101575572A priority patent/CN102250242A/zh
Priority to AU2003295025A priority patent/AU2003295025B2/en
Priority to CN2003801088861A priority patent/CN1738900B/zh
Priority to CA2506331A priority patent/CA2506331C/fr
Priority to AT08002520T priority patent/ATE494376T1/de
Priority to ES08002520T priority patent/ES2361639T3/es
Priority to JP2004552811A priority patent/JP4498144B2/ja
Priority to PCT/FR2003/003413 priority patent/WO2004046355A2/fr
Priority to EP10007471.5A priority patent/EP2239272B1/fr
Priority to EP03786019A priority patent/EP1563071B1/fr
Priority to DK03786019T priority patent/DK1563071T3/da
Priority to AT03786019T priority patent/ATE408689T1/de
Priority to ES10007471.5T priority patent/ES2454592T3/es
Priority to DE60335676T priority patent/DE60335676D1/de
Priority to ES03786019T priority patent/ES2314268T3/es
Priority to DK08002520.8T priority patent/DK1925667T3/da
Priority to EP08002520A priority patent/EP1925667B1/fr
Publication of FR2847263A1 publication Critical patent/FR2847263A1/fr
Application granted granted Critical
Publication of FR2847263B1 publication Critical patent/FR2847263B1/fr
Priority to JP2010005852A priority patent/JP5202550B2/ja
Priority to US12/907,695 priority patent/US9568482B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
FR0214374A 2002-11-18 2002-11-18 Polynucleotide specifique de la cellule pancreatique beta des ilots de langerhans Expired - Fee Related FR2847263B1 (fr)

Priority Applications (22)

Application Number Priority Date Filing Date Title
FR0214374A FR2847263B1 (fr) 2002-11-18 2002-11-18 Polynucleotide specifique de la cellule pancreatique beta des ilots de langerhans
DK03786019T DK1563071T3 (da) 2002-11-18 2003-11-18 Protein, som er specifikt for pankreatiske beta-celler fra Langerhans-öer, og anvendelser deraf
CN2011101575572A CN102250242A (zh) 2002-11-18 2003-11-18 特异于胰腺胰岛β细胞的蛋白质及其应用
AU2003295025A AU2003295025B2 (en) 2002-11-18 2003-11-18 Protein specific to pancreatic beta cells in islets of Langerhans and applications thereof
CN2003801088861A CN1738900B (zh) 2002-11-18 2003-11-18 特异于胰腺胰岛β细胞的蛋白质及其应用
CA2506331A CA2506331C (fr) 2002-11-18 2003-11-18 Proteine specifique des cellules pancreatiques beta des ilots de langerhans et ses applications
AT08002520T ATE494376T1 (de) 2002-11-18 2003-11-18 Spezielles protein der pankreatischen beta-zellen der langerhans-inseln und seine anwendungen
ES08002520T ES2361639T3 (es) 2002-11-18 2003-11-18 Proteína específica de células pancreáticas beta de los islotes de langerhans y sus aplicaciones.
JP2004552811A JP4498144B2 (ja) 2002-11-18 2003-11-18 ランゲルハンス島の膵ベータ細胞に特異的なタンパク質およびその適用
PCT/FR2003/003413 WO2004046355A2 (fr) 2002-11-18 2003-11-18 Proteine specifique des cellules pancreatiques beta des ilots de langerhans et ses applications.
EP10007471.5A EP2239272B1 (fr) 2002-11-18 2003-11-18 Protéine spécifique des cellules pancréatiques bêta des îlots de Langerhans et ses applications
EP03786019A EP1563071B1 (fr) 2002-11-18 2003-11-18 Proteine specifique des cellules pancreatiques beta des ilots de langerhans et ses applications.
US10/535,395 US7851164B2 (en) 2002-11-18 2003-11-18 Protein specific to pancreatic beta cells in islets of langerhans and applications thereof
AT03786019T ATE408689T1 (de) 2002-11-18 2003-11-18 Protein spezifisch für die pankreatischen beta- zellen der langerhans-inseln, und seine verwendungen
EP08002520A EP1925667B1 (fr) 2002-11-18 2003-11-18 Protéine spécifique des cellules pancréatiques bêta des îlots de Langerhans et ses applications
DE60335676T DE60335676D1 (de) 2002-11-18 2003-11-18 Spezielles Protein der Pankreatischen Beta-Zellen der Langerhans-Inseln und seine Anwendungen
ES03786019T ES2314268T3 (es) 2002-11-18 2003-11-18 Proteina especifica de celulas pancreaticas beta de los islotes de langerhans y sus aplicaciones.
DK08002520.8T DK1925667T3 (da) 2002-11-18 2003-11-18 Protein, som er specifikt for de pankreatiske beta-celler i de langerhanske øer, og dets anvendelser
ES10007471.5T ES2454592T3 (es) 2002-11-18 2003-11-18 Proteína específica de células beta pancreáticas de los islotes de Langerhans y sus aplicaciones
DE60323664T DE60323664D1 (de) 2002-11-18 2003-11-18 Len der langerhans-inseln, und seine verwendungen
JP2010005852A JP5202550B2 (ja) 2002-11-18 2010-01-14 ランゲルハンス島の膵ベータ細胞に特異的なタンパク質およびその適用
US12/907,695 US9568482B2 (en) 2002-11-18 2010-10-19 Antibodies specific for ZNT8

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0214374A FR2847263B1 (fr) 2002-11-18 2002-11-18 Polynucleotide specifique de la cellule pancreatique beta des ilots de langerhans

Publications (2)

Publication Number Publication Date
FR2847263A1 FR2847263A1 (fr) 2004-05-21
FR2847263B1 true FR2847263B1 (fr) 2006-01-13

Family

ID=32187667

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0214374A Expired - Fee Related FR2847263B1 (fr) 2002-11-18 2002-11-18 Polynucleotide specifique de la cellule pancreatique beta des ilots de langerhans

Country Status (12)

Country Link
US (2) US7851164B2 (https=)
EP (3) EP1563071B1 (https=)
JP (2) JP4498144B2 (https=)
CN (2) CN1738900B (https=)
AT (2) ATE494376T1 (https=)
AU (1) AU2003295025B2 (https=)
CA (1) CA2506331C (https=)
DE (2) DE60323664D1 (https=)
DK (2) DK1925667T3 (https=)
ES (3) ES2314268T3 (https=)
FR (1) FR2847263B1 (https=)
WO (1) WO2004046355A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008065544A2 (en) * 2006-09-11 2008-06-05 Mcgill University Genetic predictors of risk for type 2 diabetes mellitus
EP2118309B1 (en) * 2006-12-29 2015-01-28 The Regents of the University of Colorado, a body corporate Diagnostic and therapeutic target for autoimmune diseases and uses thereof
WO2008096009A2 (en) * 2007-02-09 2008-08-14 Mellitech Polymorphism in the slc30a8 gene
WO2009101181A2 (en) * 2008-02-14 2009-08-20 Universite Libre De Bruxelles New plasma membrane biomarkers preferentially expressed in pancreatic beta cells useful in imaging or targeting beta cells
CN102171242A (zh) * 2008-09-30 2011-08-31 诺沃-诺迪斯克有限公司 G6PC2编码的β细胞表面标签
WO2010054096A1 (en) * 2008-11-07 2010-05-14 The Cleveland Clinic Foundation Method for detecting and purifying pancreatic beta cells
CN102762731B (zh) * 2009-08-05 2018-06-22 库尔纳公司 通过抑制针对胰岛素基因(ins)的天然反义转录物来治疗胰岛素基因(ins)相关的疾病
EP2537859A1 (en) 2011-06-23 2012-12-26 Université de Mons Molecules specifically binding pancreatic beta cells biomarkers
US8852873B2 (en) 2012-04-13 2014-10-07 Diabetomics, Llc Maternal biomarkers for gestational diabetes
CN104098675A (zh) * 2013-04-03 2014-10-15 苏州偲聚生物材料有限公司 多肽、包含该多肽的检测器件和检测试剂盒
CN104098673A (zh) * 2013-04-03 2014-10-15 苏州偲聚生物材料有限公司 多肽、包含该多肽的检测器件和检测试剂盒
JP6825910B2 (ja) * 2014-03-26 2021-02-03 ヘルムホルツ・ツェントルム・ミュンヒェン・ドイチェス・フォルシュンクスツェントルム・フューア・ゲズントハイト・ウント・ウムベルト（ゲーエムベーハー）Ｈｅｌｍｈｏｌｔｚ Ｚｅｎｔｒｕｍ Ｍｕｅｎｃｈｅｎ Ｄｅｕｔｓｃｈｅｓ Ｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ ｆｕｅｒ Ｇｅｓｕｎｄｈｅｉｔ ｕｎｄ Ｕｍｗｅｌｔ （ＧｍｂＨ） Ｆｌａｔｔｏｐ（Ｆｌｔｐ）はβ細胞成熟についての新規のバイオマーカーである
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520603D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
WO2017189483A1 (en) 2016-04-25 2017-11-02 The Johns Hopkins University Znt8 assays for drug development and pharmaceutical compositions
CN106226526A (zh) * 2016-06-30 2016-12-14 深圳市亚辉龙生物科技股份有限公司 一种锌转运蛋白8抗体化学发光免疫检测试剂盒及其制备方法
EP3652540A4 (en) 2017-07-12 2021-04-07 The Johns Hopkins University PROTEOLIPOSOME-BASED ZNT8 SELF-ANTIGEN FOR DIAGNOSIS OF TYPE 1 DIABETES
WO2020037174A1 (en) * 2018-08-16 2020-02-20 The Johns Hopkins University Antibodies to human znt8
CN109734793B (zh) * 2019-03-14 2022-12-02 深圳市药品检验研究院（深圳市医疗器械检测中心） 一种ZnT8重组蛋白及其制备方法和应用
US20220340911A1 (en) * 2019-08-13 2022-10-27 Amgen Inc. Rnai constructs for inhibiting slc30a8 expression and methods of use thereof
US12366570B2 (en) 2019-10-01 2025-07-22 The Johns Hopkins University Cell-based ZNT8 assay
CA3228876A1 (en) 2021-08-20 2023-02-23 Dax Fu Cell-surface antibody to a specific biomarker of pancreatic beta-cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
NL9001083A (nl) 1990-05-04 1991-12-02 Rijksuniversiteit Beta-cel antigeen.
ZA97476B (en) * 1996-01-22 1998-07-21 Res Dev Foundation Novel methods for the characterization of compounds which stimulate STF-1 expression in pancreatic islet cells.
AU778155B2 (en) * 1999-12-13 2004-11-18 Scripps Research Institute, The Markers for identification and isolation of pancreatic islet alpha and beta cell progenitors
AU2001271284A1 (en) * 2000-06-07 2001-12-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of pancreatic cancer
CA2421576A1 (en) * 2000-09-15 2002-03-28 Curagen Corporation Human polynucleotides and polypeptides encoded thereby
WO2002060953A2 (en) * 2000-12-15 2002-08-08 Agensys, Inc. Nucleic acid and encoded zinc transporter protein entitled 108p5h8 useful in treatment and detection of cancer

Also Published As

Publication number Publication date
ES2314268T3 (es) 2009-03-16
CA2506331A1 (fr) 2004-06-03
WO2004046355A2 (fr) 2004-06-03
US7851164B2 (en) 2010-12-14
ATE408689T1 (de) 2008-10-15
EP2239272A3 (fr) 2010-12-08
EP1563071A2 (fr) 2005-08-17
DK1563071T3 (da) 2009-02-02
AU2003295025B2 (en) 2008-09-18
ES2454592T3 (es) 2014-04-11
JP2010150262A (ja) 2010-07-08
DE60335676D1 (de) 2011-02-17
ES2361639T3 (es) 2011-06-20
EP1925667A1 (fr) 2008-05-28
CN102250242A (zh) 2011-11-23
DE60323664D1 (de) 2008-10-30
JP4498144B2 (ja) 2010-07-07
JP5202550B2 (ja) 2013-06-05
AU2003295025A1 (en) 2004-06-15
CA2506331C (fr) 2015-02-17
CN1738900B (zh) 2011-07-06
FR2847263A1 (fr) 2004-05-21
JP2006506084A (ja) 2006-02-23
EP1925667B1 (fr) 2011-01-05
EP2239272A2 (fr) 2010-10-13
WO2004046355A3 (fr) 2004-09-30
DK1925667T3 (da) 2011-04-26
EP2239272B1 (fr) 2014-01-01
US20110027807A1 (en) 2011-02-03
ATE494376T1 (de) 2011-01-15
EP1563071B1 (fr) 2008-09-17
US9568482B2 (en) 2017-02-14
US20060246442A1 (en) 2006-11-02
CN1738900A (zh) 2006-02-22

Similar Documents

Publication Publication Date Title
FR2847263B1 (fr) Polynucleotide specifique de la cellule pancreatique beta des ilots de langerhans
JP2006506084A5 (https=)
US20180216084A1 (en) Hsd17b13 variants and uses thereof
KR20200073407A (ko) 돼지 정액의 품질 판별용 단일염기다형성(snp) 마커 및 이의 용도
CN101568646A (zh) 基因扩增用引物对、含有其的基因扩增用试剂及其用途
AU2012335087B2 (en) Polypeptide substrate for the detection of von Willebrand factor cleaving protease ADAMTS13
DE50111395D1 (de) Screeningverfahren
EP2502994A1 (en) Primer set for amplification of mthfr gene, mthfr gene amplification reagent comprising same, and use of same
CN102181569A (zh) 新生儿神经管畸形致病基因突变检测试剂盒及应用
CN101619350A (zh) 用于恶性肿瘤个体化用药相关基因突变检测的基因芯片及其应用
EP2055775A1 (en) Primer set for amplification of cyp2c9 gene, reagent for amplification of cyp2c9 gene comprising the same, and use of the same
CN102257392A (zh) 预防心力衰竭的方法
US10704098B2 (en) Diagnosis and treatment of genetic alterations associated with eosinophilic esophagitis
ZA200606354B (en) Method of identifying genes which promote hybrid vigour and hybrid debility and uses thereof
CN103525904A (zh) 利用高分辨熔解曲线分析技术检测线粒体乙醛脱氢酶基因分型的方法
CN106434947B (zh) Wnt5a基因作为猪产仔数性状相关检测的分子标记
KR20170048206A (ko) XBP-1(X-box binding protein 1) 유전자를 이용한 소포체 스트레스 분석용 조성물
JPWO2018199136A1 (ja) Ａｂｌ１ ｔ３１５ｉ変異の発現レベルの測定方法
EP2576817B1 (en) Methods of diagnosing algesia
CN111373053B (zh) 单免疫球蛋白白介素-1受体相关分子(sigirr)变体及其用途
CN101109705A (zh) 一种检测酒精中毒和酒精成瘾易感性的试剂盒
DE602004020603D1 (de) Verfahren zum nachweis des gens einer mutante des pankreatischen insel-amyloidproteins sowie nukleinsäuresonde und kit dafür
CN104630362A (zh) 一种精子细胞转录调控相关基因的基因检测方法
RU2014119886A (ru) Материалы и методы для обнаружения гена арилоксиалканоатдиоксигеназы (aad-12) в растениях
JP4430063B2 (ja) Ｗｆｄｃ１の変異を検出する先天性眼疾患の検査方法

Legal Events

Date Code Title Description
CL Concession to grant licences
PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

ST Notification of lapse

Effective date: 20180731